IL6 and inflammatory bowel disease: Additionally, sCA-miR-29b when injected subcutaneously also inhibits inflammation by targeting CD11c+ dendritic immune cells of inflamed mucosa and by suppressing production of IL-6, TGF-β, and IL-23 subunits, thus suggesting sCA-miR-29 as a new route in nucleic acid-based medicine for IBD treatment [131].